We also analyzed the expression of MK3 with OS, progression-free interval (PFI), and disease-specific survival (DSS) event of GBM and LGG, and the results showed that the expression of MK3 was lower from alive patients (Figures 2A–C). This evidence concerns the gene MAPKAPK3 and glioblastoma.